Novavax COVID-19 Vaccine Shows 90% Overall Efficacy, 100% Protection v. Moderate, Severe Disease in Phase 3

 

• 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest
• 91% efficacy in high-risk populations
• 100% efficacy against variants "not considered Variants of Concern/Interest"
• All COVID-19 hospitalizations/death occurred in the placebo group
• Company to host investor conference call today at 8:30 am ET

Conference Call

Novavax will host a conference call today at 8:30am ET. The dial-in numbers for the conference call are (866) 652-5200 (Domestic) or (412) 317-6060 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 7:30 p.m. ET on June 14, 2021, until 11:59 p.m. ET on June 21, 2021. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 10157478.

A webcast of the conference call can also be accessed on the Novavax website at novavax.com/events. A replay of the webcast will be available on the Novavax website until September 14, 2021.

https://www.biospace.com/article/releases/novavax-covid-19-vaccine-demonstrates-90-percent-overall-efficacy-and-100-percent-protection-against-moderate-and-severe-disease-in-prevent-19-phase-3-trial/